Although blocking TLR4 can result in the protection of wild-type mice from lethal endotoxemia and lethal E. coli induced sepsis, TLR4 inhibitors and inflammatory cytokine antagonists do not meet the expectations in clinical trials as anti-sepsis drugs [38,39]. Here, TLR4 is linked to serum lipopolysaccharide activity.